CD19+ malignancies, Blood cancer, Cancer, B-cell malignancies
CRSPCRISPR TherapeuticsCatalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for CTX112 in CD19+ malignancies, Blood cancer, Cancer, B-cell malignancies. The expected timing is based on the latest available company guidance and may change.
12/9/24- Reported preliminary data at ASH '24. 1/13/25- Engage w/ regulatory authorities. 5/6/25- Provide update in mid-2025. 11/10/25:- Phase 1 clinical trial of CTX112 in relapsed or refractory B-cell malignancies is ongoing, and a broad program update across oncology and autoimmune disease is now expected by Q4 2025. 12/22/25:- Ph1/2 LBCL data support advancing to Ph2 at 600M cells; additional oncology updates anticipated in H2 2026. 01/12/26:- B-cell malignancy Ph1/2 trial ongoing; updates expected H2 2026 and Lilly combo study planned with pirtobrutinib. 02/12/26:- Zugo-cel Ph1/2 B-cell malignancy trial and pirtobrutinib combo ongoing; oncology updates planned for H2 2026. 05/04/26:- Zugo-cel Ph1/2 B-cell malignancy trial and pirtobrutinib combo reiterated; oncology updates still anticipated H2 2026. 08/03/26:- B-cell trial continues; pirtobrutinib combo initiated; updates expected H2 2026.
Verification
Confirm timing and program details against the company announcement or filing.